Search results
Breakeven Is Near for Arlo Technologies, Inc. (NYSE:ARLO)
Simply Wall St. via Yahoo Finance· 3 hours agoOn 31 December 2023, the US$1.3b market-cap company posted a loss of US$22m for its most recent...
Hedge Funds’ Options Bets Hand Green Investors a Path to Predicting Returns
Bloomberg via Yahoo Finance· 3 hours ago(Bloomberg) -- If you want to know how your green stock portfolio is likely to perform next quarter,...
President Biden in the Days of Remembrance
The New York Sun· 18 minutes agoThe event, part of the Holocaust Museum’s Days of Remembrance, comes amid an outbreak of hostility against Jewish students, along with denunciations of Israel, on American campuses, it’s important ...
Porter takes path from need to want was he signs with ALC - The Tribune
The Ironton Tribune· 8 hours agoRock Hill Redmen All-Ohio guard Blake Porter signed a letter-of-intent on Friday to play for the...
Bill Gates Never Finished College But These Are His 5 Pearls Of Wisdom For Anyone Who Is Graduating...
Benzinga· 3 hours agoBill Gates, co-founder of Microsoft Corporation and the fifth wealthiest person in the world,...
Money isn’t enough to smooth the path for Republican candidates hoping to retake the Senate
Seattle Times· 2 hours agoFrustrated by the seemingly endless cash flowing to Democrats, Republicans aiming to retake the...
When Will BRAIN Biotech AG (ETR:BNN) Breakeven?
Simply Wall St. via Yahoo Finance· 1 hour agoThe €61m market-cap company posted a loss in its most recent financial year of €8.3m and a latest trailing-twelve-month loss of €8.4m leading to an even...
Time is running out to recognize, compensate aging atomic veterans
Military Times via Yahoo News· 3 hours agoOne thing that has remained stagnant since I began this advocacy 18 years ago is that the path to...
T.J. Hockenson ‘ahead of schedule’ in rehab from ACL injury
Vikings Wire via Yahoo Sports· 3 hours agoYou don’t rush a player like that back from an injury this severe.” The rushing back part is going...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? - EyePoint Pharmaceuticals (NASDAQ:EYPT)
Benzinga· 32 minutes agoThe data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint ...
